Kymera Therapeutics Announces Proposed Public Offering
(NasdaqGM:KYMR), WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of […]